Skip to main content

Patients with Classical Hodgkin Lymphoma with Less Than 10.5 CD20-Positive Reed–Sternberg Cells in 10 High-Power Fields Have Better Prognosis


The CD20 immunoexpression in classical Hodgkin lymphoma (CHL) is variable and it may represent an intersection between the pathophysiology of CHL and the clinical prognosis of patients. Retrospective study with 174 patients with pathological diagnosis of CHL. Clinical data were reviewed from medical records. Immunophenotypic study with CD20 were performed in two ways: hotspot count and in 10 high-power fields (HPF). The data were tabulated and the p value less than 0.05 was considered significant. The CD20-positive phenotype was found in 45 (25.9%) of the total of 174 patients with available material. Patients with CD20 positivity on neoplastic cells tend to heal earlier, particularly those with less than 10.5 cells/10 HPF (p = 0.037). Patients with CHL with less than 10.5 CD20-positive Reed-Sternberg cells in 10 HPF have better prognosis.

This is a preview of subscription content, access via your institution.

Fig. 1

Availability of Data and Materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.


  1. Engert A, Younes A (2020) Hodgkin lymphoma: a comprehensive overview, 3rd edn. Springer, Cham.

    Book  Google Scholar 

  2. Benharroch D, Nalbandyan K, Lazarev I (2015) CD20 over-expression in Hodgkin-Reed-Sternberg cells of classical Hodgkin lymphoma: the neglected quest. J Cancer 6(11):1155.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. Watanabe K, Yamashita Y, Nakayama A, Hasegawa Y, Kojima H, Nagasawa T et al (2000) Varied B-cell immunophenotypes of Hodgkin/Reed-Sternberg cells in classic Hodgkin’s disease. Histopathology 36(4):353–361.

    CAS  Article  PubMed  Google Scholar 

  4. Rassidakis GZ, Medeiros LJ, Viviani S, Bonfante V, Nadali G-P, Vassilakopoulos TP et al (2002) CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin’s disease: associations with presenting features and clinical outcome. J Clin Oncol 20(5):1278–1287.

    CAS  Article  PubMed  Google Scholar 

  5. Tzankov A, Zimpfer A, Pehrs A-C, Lugli A, Went P, Maurer R et al (2003) Expression of B-cell markers in classical Hodgkin lymphoma: a tissue microarray analysis of 330 cases. Modern Pathol 16(11):1141–1147.

    Article  Google Scholar 

  6. Tzankov A, Krugmann J, Fend F, Fischhofer M, Greil R, Dirnhofer S (2003) Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases. Clin Cancer Res 9(4):1381–1386

    CAS  PubMed  Google Scholar 

  7. Portlock CS, Donnelly GB, Qin J, Straus D, Yahalom J, Zelenetz A et al (2004) Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin’s disease. Br J Haematol 125(6):701–708.

    Article  PubMed  Google Scholar 

  8. Aldred V, Vassallo J, Froes M, Campos AHJ, Augusto Soares F (2008) CD20 expression by Hodgkin–Reed–Sternberg cells in classical Hodgkin lymphoma is related to reduced overall survival in young adult patients. Leukemia Lymphoma 49(11):2198–2202.

    CAS  Article  PubMed  Google Scholar 

  9. Canioni D, Deau-Fischer B, Taupin P, Ribrag V, Delarue R, Bosq J et al (2009) Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases. PLoS ONE 4(7):e6341.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. Elsayed AA, Asano N, Ohshima K, Izutsu K, Kinoshita T, Nakamura S (2014) Prognostic significance of CD 20 expression and Epstein-Barr virus (EBV) association in classical Hodgkin lymphoma in Japan: a clinicopathologic study. Pathol Int 64(7):336–345.

    CAS  Article  PubMed  Google Scholar 

  11. Vassallo J, Metze K, Traina F, de Souza CA, Lorand-Metze I (2002) Further remarks on the expression of CD20 in classical Hodgkin’s lymphomas. Haematologica 87(3):ELT17

    PubMed  Google Scholar 

Download references


The authors declare that they have no financial or personal relationship(s) that may have inappropriately influenced them in writing this article.

Author information

Authors and Affiliations



DFRL and CCO are responsible for the idea of the study, the respective plan of activities, review of clinical and pathological aspects of each biopsy. DFRL wrote the paper and CCO reviewed it. CCO oriented DFRL during the development of the research. All authors have approved the final article.

Corresponding author

Correspondence to Dominique Fonseca Rodrigues Lacet.

Ethics declarations

Conflict of interest

No conflict of interest to disclose.

Ethics Approval and Consent to Participate

The Clinical Hospital of Botucatu Medical School (HC-FMB-UNESP) research ethics committee approved the study under number 2.931.940.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lacet, D.F.R., Oliveira, C.C. Patients with Classical Hodgkin Lymphoma with Less Than 10.5 CD20-Positive Reed–Sternberg Cells in 10 High-Power Fields Have Better Prognosis. Indian J Hematol Blood Transfus 38, 596–600 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Hodgkin disease
  • Prognosis
  • Immunohistochemistry
  • CD20 antigen
  • Patient outcome assessment